73 results about "Brucellosis" patented technology

The invention relates to the technical field of space-time prediction, in particular to a brucellosis space-time prediction method and system based on artificial intelligence, and the method comprises the following steps: obtaining case information, calculating an incidence relation, extracting a path sequence, screening a trend direction, and matching a new case to generate prediction data. According to the method, continuous identification of a propagation path is realized by constructing a propagation incidence relation between cases and introducing a spatial directivity index, a non-trend propagation process is screened out through an angle average value and a variance, spatial consistency of path screening is enhanced, and through joint matching of spatio-temporal characteristics of newly-added cases and an existing propagation trend, the propagation path screening efficiency is improved. The sensitivity of prediction to the trend attribution of a new case is improved, the spatial directivity of a potential disease area is enhanced through reverse projection of a trend path and area positioning drop point frequency analysis, and through linkage processing of multi-level path extraction, trend judgment and area coding, the probability of occurrence of the new case is lowered. And the capturing capability of the prediction data on the propagation and evolution characteristics of the brucellosis is improved.

The invention discloses a primer group, a kit and a method for detecting brucella, and belongs to the technical field of gene detection. The primer group comprises two pairs of specific RPA (recombinase polymerase amplification) primers: a primer pair B1F1 (SEQ ID No.3) and a primer pair B1R1 (SEQ ID No.6) targeting a B1 sequence, and a primer pair B2F1 (SEQ ID No.8) and a primer pair B2R1 (SEQ ID No.11) targeting a B2 sequence. The invention also provides a kit containing the primer group, and a detection method based on the RPA-CRISPR-Cas12a. The invention also provides a kit containing the primer group and a detection method based on the RPA-CRISPR-Cas12a. According to the application, the high efficiency of RPA amplification is combined with the ultrahigh specificity of CRISPR-Cas12a detection, the defects of long time consumption, low sensitivity and easy generation of false positive in the traditional method are overcome, rapid, sensitive and specific detection of Brucella is realized, and the application has important application value in early screening and monitoring of Brucella.

The invention relates to a silicon-based nano material for targeted therapy of brucellosis as well as a preparation method and application of the silicon-based nano material. The invention relates to a preparation method of a silicon-based nano material for targeted therapy of brucellosis. The preparation method comprises the following steps: (1) preparing magnetic mesoporous silica; (2) aminating the magnetic mesoporous silica, and modifying the magnetic mesoporous silica with a responsive material and yeast beta-glucan to obtain modified magnetic mesoporous silica; and (3) carrying out antibiotic loading on the modified magnetic mesoporous silica. According to the silicon-based nano material for targeted therapy of brucellosis as well as the preparation method and the application of the silicon-based nano material, the surface of magnetic macroporous mesoporous silica is modified with yeast beta-glucan capable of targeting M cells and glutathione responsive molecules, and a drug delivery system sensitive to a brucellosis environment is synthesized; the nano-carrier has targeted targeting selectivity for delivering and releasing drugs, the activity, slow release and target cell uptake efficiency of antibiotics are ensured, and the brucellosis treatment is more accurate and efficient.

The invention relates to the technical field of markers, in particular to application of a biomarker for identifying acute stage and chronic stage of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers have obvious difference between acute and chronic brucellosis patients. The biomarkers can realize acute and chronic staging of brucellosis, are high in sensitivity and specificity, and have relatively good diagnosis efficiency. A novel molecular diagnosis tool is provided for acute and chronic staging of brucellosis, the problems that existing serological detection is low in specificity, and clinical staging cannot be accurately judged are solved, and wide application prospects are achieved.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides construction of a fusion recombinant protein ABT for preventing brucellosis and application of the fusion recombinant protein ABT in preparation of protective vaccines. The fusion recombinant protein ABT is composed of an immunological enhancement antigen and a multi-epitope tandem antigen, wherein the immunological enhancement antigen (named as A) comprises a Brucella ribosome L7 / L12 protein and a PADRE sequence; the multi-epitope tandem antigen is formed by connecting a dominant B cell epitope part (named as B), a dominant Tc cell epitope part and a dominant Th cell epitope part (named as T) in series, wherein the dominant B cell epitope part (named as B) is derived from Brucella SurA, OMP31, BP26 and Trigger factor proteins. The ABT Brucella multi-epitope subunit vaccine prepared by mixing the fusion recombinant protein ABT and an immunologic adjuvant has the characteristics of good purity, high safety and strong immunogenicity, can stimulate an organism to generate a protective antibody, and has long antibody maintenance time.

Provided herein are methods and compositions for the detection of Brucella antigen, and more particularly, to a vaccine or immunogenic composition comprising: Brucella strain from which at least a portion of the immunogenic protein DUF883 has been deleted provided in an amount sufficient to trigger an immune response against the immunogenic protein; and a pharmaceutically acceptable vaccine carrier.

In one aspect, an EID button tag is provided herein for tagging and identifying cattle as being inoculated against brucellosis, the EID button tag including: a shell having a central opening; a transponder located in the shell; a male punch having a disc-shaped punch body and a stem extending distally therefrom, the stem having a head configured for irreversible insertion into the central opening, wherein a mounting opening is formed through the punch body with a mounting channel extending distally from the mounting opening and coaxially along the stem; and, a vaccination identification button having a disc-shaped visual identification body and a mounting stem extending distally therefrom, wherein the mounting stem is configured for irreversible insertion into the mounting channel. The punch body and the visual identification body are primarily tinted with different colors to provide visual identification of a head of cattle being inoculated against brucellosis.

This invention provides a live attenuated Brucella vaccine strain M5Δ pyrE Its construction methods and applications belong to the field of biotechnology. The M5... pyrE The strain was obtained by knocking out Brucella mesenteriae strain M5. pyrE Genetically constructed and deposited at the China Center for Type Culture Collection. This invention discovers that... pyrE The gene is associated with Brucella virulence; knocking out this gene significantly weakens Brucella virulence and reduces its intracellular and mouse viability. Compared to the existing vaccine strain M5-9026, M5... pyrE The strain exhibits superior immunoprotective effects, effectively inducing humoral and Th1 cellular immune responses, and demonstrates good safety. The M5 strain constructed in this invention... pyrE This strain has promising potential as a candidate strain for a live attenuated vaccine to prevent brucellosis in animals.

This invention discloses a primer set, kit, and method for detecting Brucella, belonging to the field of gene detection technology. The primer set comprises two pairs of specific RPA primers: primer pairs B1F1 (SEQ ID No. 3) and B1R1 (SEQ ID No. 6) targeting the B1 sequence, and primer pairs B2F1 (SEQ ID No. 8) and B2R1 (SEQ ID No. 11) targeting the B2 sequence. This invention also provides a kit containing this primer set and a detection method based on RPA-CRISPR-Cas12a. This application combines the high efficiency of RPA amplification with the ultra-high specificity of CRISPR-Cas12a detection, overcoming the shortcomings of traditional methods such as long processing time, low sensitivity, and susceptibility to false positives. It achieves rapid, sensitive, and specific detection of Brucella, and has significant application value in the early screening and monitoring of brucellosis.

The invention discloses a method for preparing a sheep-derived positive serum reference of yersinia enterocolitica, obtained positive serum and application of the positive serum, and belongs to the field of veterinary medicine products. The invention aims to solve the technical problem of how to obtain the yersinia enterocolitica sheep-derived positive serum reference which is stable in titer and character and can be used for specific detection of brucella diagnostic products. Therefore, the invention provides a method for preparing the yersinia enterocolitica sheep-derived positive serum reference, which comprises the following steps: immunizing a tested sheep by using an immunizing antigen, and collecting serum of the immunized tested sheep to obtain the yersinia enterocolitica sheep-derived positive serum reference. The immune antigen is an inactivated yersinia enterocolitica obtained by inactivating the yersinia enterocolitica. The positive serum reference can be effectively applied to quality control evaluation work of brucellosis related diagnosis products, and plays a positive role in prevention and control of brucellosis.

The invention relates to the technical field of antibody titer digitization analysis, in particular to a brucellosis antibody titer digitization analysis system based on a spectrophotometric method.According to the brucellosis antibody titer digitization analysis system, a full-time reaction kinetics absorbance curve is obtained through a data acquisition module; a signal decomposition module is utilized to decouple the signal into a low-frequency trend component and a high-frequency detail component; further identifying a reaction kinetics phase state through a low-frequency trend analysis module to lock an effective reaction interval and generate first-dimension analysis data, and controlling a high-frequency detail analysis module to generate second-dimension analysis data by taking the first-dimension analysis data as a time domain gating basis; finally, the comprehensive evaluation module constructs a coupling weight model based on the reaction kinetics phase state, and fuses the two-dimensional data to generate a comprehensive antibody activity evaluation value; according to the process, a self-adaptive analysis mechanism conforming to a reaction evolution rule is constructed, and accurate determination of the titer of the antibody is realized.

Provided herein are methods, kits and systems for the detection of Brucella antigen, method for detecting brucellosis in a mammal comprising the steps of: obtaining or having obtained a biological sample suspected being infected with Brucella sp.; and detecting in the biological sample immunogenic protein DUF883 or anti-DUF883 antibodies, wherein the presence of DUF883 or anti-DUF883 antibodies are indicative that the mammal has been exposed to Brucella, e.g., to a vaccine or immunogenic composition comprising: immunogenic protein DUF883 provided in an amount sufficient to trigger an immune response against the immunogenic protein; and a pharmaceutically acceptable vaccine carrier.

The application discloses an ELISA antibody detection kit for identifying Brucella gene deletion live vaccine (M5-90△26 strain) and wild strains and application. The kit comprises enzyme-linked reaction plate 1 and enzyme-linked reaction plate 2. The enzyme-linked reaction plate 1 is coated with LPS extracted from the Brucella gene deletion live vaccine (M5-90△26 strain), and the enzyme-linked reaction plate 2 is coated with a Brucella BP26 antigen epitope polypeptide combination composed of polypeptides with amino acid sequences shown in SEQ ID NO:1-2. The application is suitable for goats and sheep inoculated with the Brucella gene deletion live vaccine (M5-90△26 strain), can effectively distinguish the antibody produced by the Brucella gene deletion live vaccine (M5-90△26 strain) and the antibody produced by wild strain infection, thereby realizing identification and detection, being favorable for prevention and control of brucellosis and optimization of a vaccination strategy, and providing technical support for healthy and sustainable development of animal husbandry.

The present invention provides a classification model for sheep echinococcosis and sheep brucellosis based on serum Raman spectroscopy, a method for establishing the model, and a detection device. The method for establishing the classification model for sheep echinococcosis and sheep brucellosis based on serum Raman spectroscopy comprises: (1) collecting blood from healthy sheep and diseased sheep, extracting serum, and obtaining serum samples; (2) detecting the serum samples using a laser Raman spectrometer to obtain Raman spectral data; (3) performing noise reduction, baseline correction, and normalization on the Raman spectral data to obtain pre-processed spectral data; (4) performing principal component analysis (PCA) dimensionality reduction on the processed spectral data, and then establishing a linear discriminant analysis (LDA) or support vector machine (SVM) classification model to obtain a classification model for sheep echinococcosis and sheep brucellosis. The classification model and detection device established by the present invention based on machine learning algorithms and Raman spectroscopy have potential in screening sheep infected with echinococcosis and sheep infected with brucellosis.

The present invention provides a Brucellosis cell immune protein and use thereof. In the present invention, firstly, a Brucellosis cell immune protein with relatively high immunogenicity is screened by means of antibody spectrum technology; then, the protein gene sequence of Brucella are subjected to fusion expression by using molecular biology technology, so as to improve the ability for producing an immune response which is induced by an antigen; next, the antigen is expressed in vitro and then subjected to multi-stage purification, and the obtained purified protein is used as a stimulant; and finally, anti-coagulated blood from an immunized animal is collected, the stimulant is added thereto, the mixture is incubated for 24 hours at 37° C., the resulting product is centrifuged to collect a supernatant, and the level of IL-17 in the supernatant is detected by an ELISA method.

The invention provides a specific polypeptide of Brucella, the amino acid sequence of the specific polypeptide is as shown in SEQ ID No.1, and the specific polypeptide is derived from BMEI1871 protein of Brucella. The invention also provides a recombinant vector or an expression cassette for expressing the specific polypeptide, and a recombinant cell or a recombinant bacterium. The invention verifies the application of the specific polypeptide in preparation of drugs or reagents for preventing, detecting or diagnosing brucellosis, and also provides an ELISA (enzyme-linked immuno sorbent assay) detection kit for detecting brucellosis. According to the present invention, the specific polypeptide of the brucella BMEI1871 protein is adopted as the antigen to establish the ELISA method for detecting the brucella antibody, such that the accuracy is high, and the powerful support is provided for brucellosis purification. The antigen source is convenient, the stability is high, the repeatability is strong, and the defects of using whole bacteria or lipopolysaccharide as the antigen are overcome.

The invention belongs to the technical field of biological medicines, and particularly relates to a lactic acid bacteria live vector vaccine for preventing and treating brucellosis and a preparation method of the lactic acid bacteria live vector vaccine. The lactic acid bacteria live vector vaccine is obtained by transferring expression vectors for expressing Brucella omp19 protein and BvrR protein into lactic acid bacteria, and the lactic acid bacteria are lactobacillus cavings. The lactobacillus live vector vaccine for preventing and treating brucellosis is constructed by taking brucella omp19 protein and BvrR protein as immunogens and lactic acid bacteria as an antigen transfer vector, and the safety is good. After the vaccine is used for immunizing mice, the mice can obtain a higher antibody level, the duration is long, brucella infection is effectively inhibited, meanwhile, the production process of the vaccine is simplified, and the vaccine has a good application prospect.

The present application relates to the field of animal breeding technology, and particularly relates to a molecular marker related to sheep brucellosis susceptibility and application thereof.The molecular marker comprises nucleic acid of a nucleotide sequence as shown in SEQ ID NO.1, and polymorphism exists at the 101st position, and the polymorphism is G / A.A molecular marker related to sheep brucellosis susceptibility is screened by the present application, and the susceptibility of sheep brucellosis can be identified by detecting the polymorphism of the molecular marker.The molecular marker provided by the present application can also be used for breeding sheep varieties with low brucellosis susceptibility, which has important significance in the field of sheep breeding.

The present application relates to the field of animal breeding technology, and particularly relates to a molecular marker and application thereof in identifying sheep brucellosis susceptibility. The molecular marker comprises nucleic acid of a nucleotide sequence shown as SEQ ID NO. 1, and a polymorphism exists at the 101th position, and the polymorphism is C / G. The present application identifies a molecular marker related to sheep brucellosis susceptibility. By analyzing the genetic polymorphism of the marker, the susceptibility of sheep individuals to brucellosis can be determined. In addition, the molecular marker can also be used as an effective auxiliary selection tool, and is applied to breeding of new sheep strains with stronger brucellosis resistance, which has important application value for disease-resistant breeding of sheep.

The utility model discloses a brucellosis pathogen culture device, which belongs to the technical field of microorganism culture and comprises a culture box, two symmetrically distributed connecting frames are fixedly connected to the inner walls of the two sides of the culture box, a plurality of culture dishes are arranged between the two connecting frames, a transverse plate is fixedly connected to the tops of the two connecting frames, and the transverse plate is fixedly connected to the bottom of the culture box. Through the design of the height adjusting assembly, up-down movement of the culture dish in the incubator is achieved, the problem that the culture dish is inconvenient to take due to the fact that the height of the incubator is too high is effectively solved, an experimenter does not need to frequently stand on tiptoes or bend down or use tools such as a ladder, and the height of the culture dish can be easily adjusted only through simple operation of a PLC. The operation complexity is greatly reduced, through the design of a stable transmission system and a clamping plate, the safety and stability of the culture dish in the moving process are ensured, damage to the culture dish and leakage of pathogens are effectively avoided, and the reliability and safety of experiments are improved.

The invention relates to the technical field of Tibetan medicine preparations, in particular to a Tibetan medicine composition for treating rheumatoid arthritis and a preparation method. The Tibetan medicine composition is prepared from 18 Tibetan medicines including fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit and the like according to a specific weight ratio, and the monarch, minister, assistant and guide relationship is defined based on the Tibetan medicine true brucellosis theory; according to the preparation method, a low-temperature superfine grinding and step-by-step extraction process is innovatively adopted, three dosage forms of powder, a nano drug-loaded emulsion and a temperature-sensitive acupoint patch are developed, and a dual quality control system of HPLC (High Performance Liquid Chromatography) content determination and fingerprint spectrum is established. TNF-alpha and IL-6 target spots and nf-kb and PI3K-AKT inflammation pathways are synergistically regulated and controlled through multiple components, joint swelling and bone erosion are relieved, and gastrointestinal tract side effects of western medicines are avoided; the transdermal absorption efficiency is improved by a nano drug-loading technology, acupoint targeted drug delivery is realized by the temperature-sensitive patch, and verification shows that the joint swelling inhibition rate is greater than or equal to 70%, the inflammatory factor decrease amplitude is greater than or equal to 50%, and the patch is suitable for patients with mild, moderate and severe rheumatoid arthritis and has a wide clinical application prospect.

The application relates to the technical field of markers, in particular to application of biomarkers for identifying acute and chronic stages of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers are significantly different between patients with acute and chronic brucellosis. The biomarkers can be used to realize acute and chronic staging of brucellosis, and have high sensitivity and specificity and good diagnostic efficiency. The application provides a new molecular diagnostic tool for acute and chronic staging of brucellosis, solves the problems of low specificity of existing serological detection and incapability of accurately judging clinical stages, and has a wide application prospect.

This invention relates to the field of veterinary biological products, specifically to a live attenuated strain of Brucella brucellosis RB39, its applications, vaccines, antigens, and kits. The live attenuated Brucella brucellosis RB39 of this invention can be used to prepare a highly safe vaccine that can be injected into pregnant animals and provides good immunoprotection. Furthermore, this vaccine is suitable for immunization of multiple animal species. In addition, based on the live attenuated Brucella brucellosis RB39 of this invention, an antigen can be prepared to identify Brucella brucellosis antibodies, effectively distinguishing between vaccine immunization and natural infection, providing a scientific basis for brucellosis prevention and control.

The invention discloses a Brucella specific amplification primer pair, a visual detection product and a detection method, and relates to the technical field of biological detection. The Brucella specific amplification primer pair comprises an upstream primer of which the nucleotide sequence is shown as SEQ ID NO.2 and a downstream primer of which the nucleotide sequence is shown as SEQ ID NO.3; iSp18 modification exists between the 18th nucleotide and the 19th nucleotide of the upstream primer; and iSp18 modification exists between the 18th nucleotide and the 19th nucleotide of the downstream primer. The Brucella specific amplification primer pair can be applied to visual detection of Brucella, has the advantages of strong specificity, high sensitivity and good accuracy, has good practical application value in the aspect of early detection of brucellosis, and can provide a quicker detection means for prevention and control of brucellosis.

The application relates to the field of biological medicine, and particularly discloses an oral double-targeting brucellosis nano-vaccine CS-CKS9-MEV-DCpep-NPs construction method and application thereof, the nano-vaccine comprises chitosan nanoparticles and a double-targeting peptide vaccine CKS9-MEV-DCpep encapsulated in the chitosan nanoparticles, the double-targeting peptide vaccine CKS9-MEV-DCpep comprises, from N-terminal to C-terminal, an M cell targeting peptide CKS9, a polyepitope vaccine MEV and a DC targeting peptide DCpep; the application also provides a method for constructing the nano-vaccine and application thereof. The application successfully constructs the oral CS-CKS9-MEV-DCpep-NPs nano-vaccine through a systematic strategy of integrating 'bioinformatics precise screening, double-targeting molecular modification and excellent carrier delivery', the nano-vaccine has double-targeting functions of mucosal immunity and cellular immunity, can effectively induce mucosal immunity, cellular immunity and humoral immunity, and exhibits excellent protection efficacy in acute and chronic infection models, thereby providing a new effective solution for brucellosis prevention and control.

The invention discloses a monoclonal antibody combination for Brucella detection and application thereof, and belongs to the technical field of immunodetection. The monoclonal antibody combination disclosed by the invention comprises a monoclonal antibody 15F4 and a monoclonal antibody 32H9. On the basis of the monoclonal antibody combination, a double-antibody sandwich ELISA detection method with 15F4 as a capture antibody and enzyme-labeled 32H9 as a detection antibody is established, and key parameters such as coating concentration, closing conditions, incubation and color development time and the like are optimized. The method has high specificity on brucella, and does not cross with common cross-reactive bacteria such as escherichia coli O: 157, salmonella and the like; the sensitivity is high, and the detection limit can reach 1 * 10 < 5 > CFU / mL; the repeatability is good, and the intra-batch and inter-batch variation coefficients are both smaller than 10%. The invention provides a core reagent and a reliable means for early, rapid and accurate diagnosis of brucellosis, and is suitable for on-site screening of clinical samples and animal epidemic diseases.

This invention relates to a colloidal gold test strip for detecting sheep pox virus antibodies, its preparation method, and its application. First, this invention prepares recombinant 122 protein, which exhibits significant antigenicity and immunogenicity, making it a good target for diagnosing sheep pox virus. Second, this invention prepares a colloidal gold test strip for detecting sheep pox virus antibodies. The test strip has a PVC base plate with a sample pad, a gold-labeled pad, a nitrocellulose membrane, and an absorbent pad arranged sequentially. The gold-labeled pad is coated with gold-labeled recombinant 122 protein. The test strip of this invention can simultaneously detect antibodies against sheep pox virus, bovine nodular dermatosis virus, and goat pox virus, with sensitivities of 1:128, 1:128, and 1:64, respectively. It shows no cross-reactivity with bovine viral diarrhea virus, foot-and-mouth disease virus type O, foot-and-mouth disease virus type A, sheep stomatitis virus, brucellosis, and Escherichia coli, exhibiting good specificity and a diagnostic concordance rate of 93%.

The present application relates to the field of animal breeding technology, and particularly relates to a SNP molecular marker related to the anti-Brucella disease trait of sheep and application thereof.The molecular marker comprises nucleic acid of the nucleotide sequence shown in SEQ ID NO.1, and polymorphism exists at the 101th position, and the polymorphism is T / C.A molecular marker is disclosed, and the molecular marker is related to the anti-Brucella disease trait of sheep.The polymorphism detection result of the molecular marker reflects the anti-Brucella disease trait of sheep.Therefore, based on the correlation between the polymorphism of the molecular marker and the anti-Brucella disease trait of sheep, the sheep germplasm resource can be improved, and the present application has important application value.

The present application relates to the field of biotechnology, and particularly relates to a Brucella attenuated live vaccine strain M5Delta lysR21 and an attenuating method and application thereof, wherein the M5Delta lysR21 is obtained by deleting a lysR21 gene from a M5 strain of ovine Brucella, and the Brucella attenuated live vaccine strain MSDelta lysR21 is preserved in the China General Microbiological Culture Collection Center, located at No. 1, Beichen West Road, Yard 3, Chaoyang District, Beijing, on November 21, 2024, with a preservation number of CGMCC NO. 32791. It is found in the present application that the lysR21 gene is related to the virulence of Brucella, and the deletion of the lysR21 gene can weaken the virulence of Brucella, can significantly reduce the survival ability of Brucella in cells and in mice, and shows stronger immunoprotective property than a vaccine strain, and can be used as a candidate attenuated live vaccine strain for preventing animal brucellosis, and has potential application value.

This invention belongs to the field of microbial technology, specifically relating to a Brucella-deficient strain 104MΔBioZ, its construction method, and its applications. The Brucella-deficient strain 104MΔBioZ is formed by knocking out a gene involved in biotin synthesis in the Brucella 104M genome. BioZ The strain obtained after gene sequencing; the strain involved in biotin synthesis BioZ The nucleotide sequence of the gene is shown in SEQ ID NO:1. This invention utilizes the knockout of biotin synthesis in Brucella 104M. BioZ A mutant strain was obtained through gene synthesis. The resulting mutant strain exhibited significantly reduced virulence compared to Brucella 104M and demonstrated highly effective resistance to infection by the parent Brucella. Results showed that immunizing healthy mice with the 104MΔBioZ strain described in this invention for brucellosis prevention is safe and provides high protection. The Brucella-deficient strain 104MΔBioZ has broad application prospects in the field of brucellosis prevention and control.